{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:54:41Z","timestamp":1792122881373,"version":"4.4.0"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites and peritoneal implants, primarily arising from ruptured appendiceal neoplasms. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the preferred treatment for resectable and operable cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An international panel from the Peritoneal Surface Oncology Group International (PSOGI), the International Society for the Study of Pleura and Peritoneum (ISSPP), the Society of Surgical Oncology (SSO), the European Society of Surgical Oncology (ESSO), and EURACAN used the GRADE methodology and ADOLOPMENT approach to adapt existing guidelines. Clinical questions were framed using the PICO framework, and systematic reviews were conducted. Evidence certainty and the balance of benefits and harms were evaluated with the Evidence\u2010to\u2010Decision framework.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A strong recommendation was made for CRS and HIPEC over debulking surgery for resectable PMP. Observational studies reported 5\u2010 and 10\u2010year survival rates of 80% and 55%, respectively, with CRS and HIPEC, compared to lower outcomes with debulking. Despite the very low certainty of evidence, the panel strongly endorses CRS and HIPEC over debulking surgery. This recommendation is driven by PMP's known chemoresistance, the lack of viable alternative treatments, and the survival benefits observed in observational studies coming only from radical surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This consensus endorses CRS and HIPEC as the standard of care for operable and resectable PMP. This recommendation will increase acceptance and awareness among a broader audience of healthcare professionals about the potential benefits of this treatment in managing this rare peritoneal disease.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.28167","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T12:28:33Z","timestamp":1755347313000},"page":"810-816","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-277X","authenticated-orcid":false,"given":"Shigeki","family":"Kusamura","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori Milano Milano Lombardia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Levine","sequence":"additional","affiliation":[{"name":"Section of Surgical Oncology, Department of Surgery Wake Forest University School of Medicine Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9478","authenticated-orcid":false,"given":"Michela","family":"Cinquini","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Lombardia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, H\u00f4pital Lyon Sud Service de Chirurgie Digestive Lyon Auvergne\u2010Rh\u00f4ne\u2010Alpes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompiliu","family":"Piso","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery Hospital Barmherzige Br\u00fcder Regensburg Bavaria Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-2584","authenticated-orcid":false,"given":"Andreas","family":"Brandl","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery University Hospital Heidelberg Heidelberg Baden\u2010W\u00fcrttemberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-2006","authenticated-orcid":false,"given":"Claudio","family":"Quadros","sequence":"additional","affiliation":[{"name":"Sao Rafael Hospital Bahia State University Salvador Bahia Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery La Piti\u00e9 Salp\u00eatri\u00e8re Hospital Paris \u00cele\u2010de\u2010France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faheez","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Institute Basingstoke North Hampshire Hospital Foundation Trust Basingstoke Hampshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice","family":"Eveno","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery University Hospital of Lille Lille Hauts\u2010de\u2010France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori Milano Milano Lombardia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9810","authenticated-orcid":false,"given":"Marcello","family":"Guaglio","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori Milano Milano Lombardia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori Milano Milano Lombardia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Moran","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Institute Basingstoke North Hampshire Hospital Foundation Trust Basingstoke Hampshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1245\/s10434-020-08655-8","article-title":"Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method","volume":"28","author":"Patrick\u2010Brown T. D. J. H.","year":"2021","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/his.13324","article-title":"The Histopathological Classification, Diagnosis and Differential Diagnosis of Mucinous Appendiceal Neoplasms, Appendiceal Adenocarcinomas and Pseudomyxoma Peritonei","volume":"71","author":"Carr N. J.","year":"2017","journal-title":"Histopathology"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.006","article-title":"Targeting Hypoxia\u2010Mediated Mucin 2 Production as a Therapeutic Strategy for Mucinous Tumors","volume":"169","author":"Dilly A. K.","year":"2016","journal-title":"Translational Research"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/biomedicines11072049","article-title":"A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei","volume":"11","author":"Kusamura S.","year":"2023","journal-title":"Biomedicines"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179510","article-title":"Bilateral Blockade of MEK\u2010 and PI3K\u2010mediated Pathways Downstream of Mutant KRAS as a Treatment Approach for Peritoneal Mucinous Malignancies","volume":"12","author":"Kuracha M. R.","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.prp.2015.06.004","article-title":"A Mutation Spectrum That Includes GNAS, KRAS and TP53 may be Shared by Mucinous Neoplasms of the Appendix","volume":"211","author":"Hara K.","year":"2015","journal-title":"Pathology \u2010 Research and Practice"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00000658-199402000-00002","article-title":"Pseudomyxoma Peritonei Long\u2010Term Patient Survival With an Aggressive Regional Approach","volume":"219","author":"Gough D. B.","year":"1994","journal-title":"Annals of Surgery"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/ejso.2000.1038","article-title":"Cytoreductive Surgery and Peri\u2010Operative Intraperitoneal Chemotherapy as a Curative Approach to Pseudomyxoma Peritonei Syndrome","volume":"27","author":"Sugarbaker P. H.","year":"2001","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jss.2012.12.040","article-title":"Improved Survival of Patients With Pseudomyxoma Peritonei Receiving Intraperitoneal Chemotherapy With Cytoreductive Surgery: A Systematic Review and Meta\u2010Analysis","volume":"183","author":"McBride K.","year":"2013","journal-title":"Journal of Surgical Research"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early\u2010 and Long\u2010Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"30","author":"Chua T. C.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal Tumours and Pseudomyxoma Peritonei: Literature Review With PSOGI\/EURACAN Clinical Practice Guidelines for Diagnosis and Treatment","volume":"47","author":"Govaerts K.","year":"2021","journal-title":"European Journal of Surgical Oncology"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) Frameworks for Adoption, Adaptation, and De Novo Development of Trustworthy Recommendations: GRADE\u2010ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann H. J.","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27947"},{"key":"e_1_2_8_15_1","unstructured":"Linea guida AIOM Tumori Peritoneali https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-peritoneali-primitivi-e-secondari\/."},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/1097-0142(19920715)70:2<396::AID-CNCR2820700205>3.0.CO;2-A","article-title":"Pseudomyxoma Peritonei of Appendiceal Origin. The Memorial Sloan\u2010Kettering Cancer Center Experience","volume":"70","author":"Smith J. W.","year":"1992","journal-title":"Cancer"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00000478-200308000-00006","article-title":"Appendiceal Mucinous Neoplasms: A Clinicopathologic Analysis of 107 Cases","volume":"27","author":"Misdraji J.","year":"2003","journal-title":"The American Journal of Surgical Pathology"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","article-title":"Long\u2010Term Survival Following Treatment of Pseudomyxoma Peritonei: An Analysis of Surgical Therapy","volume":"241","author":"Miner T. J.","year":"2005","journal-title":"Annals of Surgery"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00384-014-1933-8","article-title":"Comparison of Serial Debulking and Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei of Appendiceal Origin","volume":"29","author":"J\u00e4rvinen P.","year":"2014","journal-title":"International Journal of Colorectal Disease"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1463-1318.2009.01947.x","article-title":"Survival of Patients with Pseudomyxoma Peritonei Treated by Serial Debulking","volume":"12","author":"J\u00e4rvinen P.","year":"2010","journal-title":"Colorectal Disease"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/ejcn.2015.97","article-title":"Palliative Parenteral Nutrition use in Patients With Intestinal Failure as a Consequence of Advanced Pseudomyxoma Peritonei: A Case Series","volume":"69","author":"Disney B. R.","year":"2015","journal-title":"European Journal of Clinical Nutrition"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1245\/s10434-007-9768-y","article-title":"HIPEC: The Complexities of Clinical Trials","volume":"15","author":"Bartlett D. L.","year":"2008","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.6000\/1929-6029.2015.04.02.7","article-title":"Using Propensity Score Matching in Clinical Investigations: A Discussion and Illustration","volume":"4","author":"Hosman C.","year":"2015","journal-title":"International Journal of Statistics in Medical Research"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hast.4911","article-title":"Synthetic Health Data: Real Ethical Promise and Peril","volume":"54","author":"Susser D.","year":"2024","journal-title":"Hastings Center Report"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/sim.4363","article-title":"Bayesian Adaptive Clinical Trials: A Dream for Statisticians Only?","volume":"31","author":"Chevret S.","year":"2012","journal-title":"Statistics in Medicine"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura S.","year":"2021","journal-title":"JAMA Surgery"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.ejso.2015.09.005","article-title":"Cytoreductive Surgery with a Hyperthermic Intraperitoneal Chemotherapy Program: Safe After 40 Cases, but Only Controlled After 140 Cases","volume":"41","author":"Voron T.","year":"2015","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","article-title":"Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS\u00ae) Society Recommendations \u2014 Part I: Preoperative and Intraoperative Management","volume":"46","author":"H\u00fcbner M.","year":"2020","journal-title":"European Journal of Surgical Oncology"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/DCR.0b013e3182a62b0d","article-title":"Complete Cytoreduction for Pseudomyxoma Peritonei Is Optimal but Maximal Tumor Debulking May be Beneficial in Patients in Whom Complete Tumor Removal Cannot be Achieved","volume":"56","author":"Dayal S.","year":"2013","journal-title":"Diseases of the Colon & Rectum"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1245\/s10434-017-6305-5","article-title":"Clinical Surveillance After Macroscopically Complete Surgery for Low\u2010Grade Appendiceal Mucinous Neoplasms (LAMN) With or Without Limited Peritoneal Spread: Long\u2010Term Results in a Prospective Series","volume":"25","author":"Guaglio M.","year":"2018","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108600","article-title":"The Risk of Developing Pseudomyxoma Peritonei From a Non\u2010Perforated Low Grade Appendiceal Mucinous Neoplasm Found at Appendicectomy","volume":"50","author":"Lakmal C.","year":"2024","journal-title":"European Journal of Surgical Oncology"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4613-1247-5_15","volume-title":"Peritoneal Carcinomatosis: Principles of Management. Vol 82. Cancer Treatment and Research","author":"Sugarbaker P. H.","year":"1996"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15880-y"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.5812\/jhealthscope-129176"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jso.27833","article-title":"Education and Training in Peritoneal Surface Oncology","volume":"130","author":"Gonz\u00e1lez\u2010Moreno S.","year":"2024","journal-title":"Journal of Surgical Oncology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.22376\/ijpbs\/lpr.2022.12.6.L29-35"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.soc.2024.10.002","article-title":"Disparities and Health Care Delivery for Patients With Peritoneal Surface Malignancy","volume":"34","author":"Deeb A.\u2010P.","year":"2025","journal-title":"Surgical Oncology Clinics of North America"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jso.26506","article-title":"Treatment of Advanced Pseudomyxoma Peritonei Using Cytoreductive Surgery Including Total Gastrectomy and Perioperative Chemotherapy","volume":"124","author":"Sugarbaker P. H.","year":"2021","journal-title":"Journal of Surgical Oncology"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1245\/s10434-024-15646-6","article-title":"The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei","volume":"31","author":"Kusamura S.","year":"2024","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/jso.27850","article-title":"A Combinatorial Culture Strategy to Develop Pseudomyxoma Peritonei Organoid Models","volume":"130","author":"Varinelli L.","year":"2024","journal-title":"Journal of Surgical Oncology"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","article-title":"Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study","volume":"27","author":"Forsythe S. D.","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/apm.12653","article-title":"Carbonic Anhydrase Ii: a Novel Biomarker for Pseudomyxoma Peritonei","volume":"125","author":"J\u00e4rvinen P.","year":"2017","journal-title":"APMIS"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000332739","article-title":"Leptin, MUC2 and mTOR in Appendiceal Mucinous Neoplasms","volume":"79","author":"Chang M. S.","year":"2012","journal-title":"Pathobiology"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/annonc\/mdw314","article-title":"Toward the Molecular Dissection of Peritoneal Pseudomyxoma","volume":"27","author":"Pietrantonio F.","year":"2016","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-023-00465-4","article-title":"Antitumor Effect of a Small\u2010Molecule Inhibitor of KRASG12D in Xenograft Models of Mucinous Appendicular Neoplasms","volume":"12","author":"V\u00e1zquez\u2010Borrego M. C.","year":"2023","journal-title":"Experimental Hematology & Oncology"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide Vaccine Targeting Mutated GNAS: A Potential Novel Treatment for Pseudomyxoma Peritonei","volume":"9","author":"Flatmark K.","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmoldx.2018.05.002","article-title":"Analysis of Mutation and Loss of Heterozygosity by Whole\u2010Exome Sequencing Yields Insights Into Pseudomyxoma Peritonei","volume":"20","author":"Pengelly R. J.","year":"2018","journal-title":"The Journal of Molecular Diagnostics"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1159\/000536219","article-title":"Genome\u2010Wide Analysis of DNA Methylation in Pseudomyxoma Peritonei Originated From Appendiceal Neoplasms","volume":"102","author":"Takane K.","year":"2024","journal-title":"Oncology"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/cncr.32881","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms","volume":"126","author":"Chicago Consensus Working Group","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dld.2021.10.005","article-title":"Appendiceal Tumors and Pseudomyxoma Peritonei: French Intergroup Clinical Practice Guidelines for Diagnosis, Treatments and Follow\u2010Up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)","volume":"54","author":"Delhorme J.\u2010B.","year":"2022","journal-title":"Digestive and Liver Disease"},{"key":"e_1_2_8_51_1","unstructured":"F.KoberandT.Bachleitner\u2010Hofmann Leitlinie zur Behandlung von Patienten mit peritonealen Neoplasmen mittels zytoreduktiver Chirurgie und hyperthermer intraperitonealer Chemotherapie in \u00d6sterreich."}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.28167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:41:08Z","timestamp":1759830068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.28167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jso.28167"],"URL":"https:\/\/doi.org\/10.1002\/jso.28167","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"2024-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}